Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

siRNA firm Switch Therapeutics enters the chat

by Shi En Kim
March 25, 2023 | A version of this story appeared in Volume 101, Issue 10

 

Switch Therapeutics has launched with a $52 million series A. The California start-up aims to treat diseases by suppressing gene expression using cell-selective, noncoding double-stranded oligonucleotides known as small interfering RNA (siRNA). Switch’s lead program is geared toward central nervous system conditions.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.